Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSinclair Pharma Regulatory News (SPH)

  • There is currently no data for SPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Sinclair Pharma Plc

22 Oct 2018 12:00

RNS Number : 7358E
Peel Hunt LLP
22 October 2018
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Peel Hunt LLP

(b) Name of offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Sinclair Pharma Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Sinclair Pharma Plc

(d) Date dealing undertaken:

19 October 2018

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

 

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Buy

46,519

31.62 GBx

31.53 GBx

Ordinary Shares

Sell

500

31.79 GBx

31.79 GBx

 

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

22 October 2018

Contact name:

Alec Whitelaw

Telephone number:

02074188860

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERFKBDNOBDKKKB
Date   Source Headline
12th Jul 20185:06 pmRNSForm 8.3 Sinclair Pharma plc Replacement
12th Jul 20185:05 pmRNSForm 8.3 Sinclair Pharma plc Replacement
12th Jul 201812:17 pmRNSForm 8.3 - Sinclair Pharma plc
12th Jul 201812:17 pmRNSForm 8.3 - Sinclair Pharma PLC
12th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
11th Jul 20182:20 pmRNSForm 8.3 - Sinclair Pharma Plc
11th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
11th Jul 20189:11 amRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc - Restated
11th Jul 20188:19 amRNSForm 8.5 (EPT/RI) - Sinclar Pharma Plc
10th Jul 20183:01 pmRNSForm 8.3 - Sinclair Pharma plc
10th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
10th Jul 201810:32 amRNSForm 8.5 (EPT/RI) - Sinclar Pharma Plc
9th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
6th Jul 20183:42 pmBUSForm 8.3 - SINCLAIR PHARMA PLC
6th Jul 20183:37 pmRNSForm 8.3 - Sinclair Pharma plc
6th Jul 20182:15 pmRNSForm 8.3 - [Sinclair Pharma plc]
6th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
6th Jul 201810:30 amRNSForm 8.3 - Sinclair Pharma Plc
5th Jul 20186:03 pmRNSStatement re Possible Offer
5th Jul 20181:32 pmRNSStatement re Possible Offer
5th Jul 20187:00 amRNSTrading Update
13th Jun 201811:06 amRNSResult of AGM
13th Jun 20187:00 amRNSAGM Statement
23rd May 20188:00 amRNSSilhouette Instalift wins NewBeauty Magazine Award
18th May 20188:00 amRNSPublication of Annual Report and Accounts
30th Apr 20187:01 amRNSFinal Results
30th Apr 20187:00 amRNSSinclair secures Euro23 million debt facility
26th Mar 20187:00 amRNSUpdate on US distribution of Silhouette Instalift
6th Mar 20187:00 amRNSHolding(s) in Company
2nd Mar 20187:00 amRNSHolding(s) in Company
1st Mar 201810:06 amRNSHolding(s) in Company
22nd Feb 20187:01 amRNSSinclair announces $5m investment by EW Healthcare
22nd Feb 20187:00 amRNSSinclair and ThermiGen terminate agreement
17th Jan 20187:00 amRNSDirector/PDMR Shareholding
16th Jan 20182:15 pmRNSDirector/PDMR Shareholding
16th Jan 20187:00 amRNSEllansé® Approved for Sale in Brazil
15th Jan 20187:00 amRNSTrading Statement
19th Oct 20172:25 pmRNSNew CE mark granted for Silhouette Soft
2nd Oct 20177:15 amRNSHardman Research: Demand growing in target markets
19th Sep 20177:00 amRNSInterim Results
12th Jul 20177:47 amRNSHolding(s) in Company
12th Jul 20177:15 amRNSHardman Research: Promising start in the US
11th Jul 20177:00 amRNSTrading Update for the 6 months to 30 June 2017
5th Jul 20177:00 amRNSHolding(s) in Company
19th Jun 20177:00 amRNSAcquisition
14th Jun 20177:00 amRNSHolding(s) in Company
24th May 20177:00 amRNSHolding(s) in Company
26th Apr 201710:50 amRNSResult of AGM
30th Mar 20174:55 pmRNSAnnual Financial Report
30th Mar 20177:00 amRNSAdditional listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.